Question 1

When is mirtazapine a better first choice than an SSRI for my anxious patient?

Accepted Answer

Mirtazapine is not first-line for uncomplicated GAD, but is strategically valuable in specific contexts: anxious depression with severe insomnia (H1-mediated sedation at 7.5-15 mg), cachexia or weight loss (appetite stimulation), geriatric anxiety-depression, and SSRI augmentation for treatment resistance. Its dual mechanism — alpha-2 autoreceptor blockade increasing noradrenaline and serotonin release, plus postsynaptic 5-HT2A/2C/3 antagonism directing serotonin to the anxiolytic 5-HT1A receptor — bypasses reuptake inhibition entirely. The dose-sedation paradox (7.5-15 mg heavily sedating; 30-45 mg less sedating due to noradrenergic offset) requires careful dose selection. Open-label GAD data show 79.5% response rate, but double-blind trials have not robustly replicated this. No sexual dysfunction is a genuine advantage over SSRIs. Combination with SSRIs/SNRIs ('California rocket fuel') is pharmacologically rational but requires monitoring for additive sedation.

Question 2

How does mirtazapine's dual mechanism produce anxiolysis?

Accepted Answer

Mirtazapine is not first-line for uncomplicated GAD, but is strategically valuable in specific contexts: anxious depression with severe insomnia (H1-mediated sedation at 7.5-15 mg), cachexia or weight loss (appetite stimulation), geriatric anxiety-depression, and SSRI augmentation for treatment resistance. Its dual mechanism — alpha-2 autoreceptor blockade increasing noradrenaline and serotonin release, plus postsynaptic 5-HT2A/2C/3 antagonism directing serotonin to the anxiolytic 5-HT1A receptor — bypasses reuptake inhibition entirely. The dose-sedation paradox (7.5-15 mg heavily sedating; 30-45 mg less sedating due to noradrenergic offset) requires careful dose selection. Open-label GAD data show 79.5% response rate, but double-blind trials have not robustly replicated this. No sexual dysfunction is a genuine advantage over SSRIs. Combination with SSRIs/SNRIs ('California rocket fuel') is pharmacologically rational but requires monitoring for additive sedation.

Question 3

For which patient profile is the weight gain-sedation trade-off acceptable?

Accepted Answer

Mirtazapine is not first-line for uncomplicated GAD, but is strategically valuable in specific contexts: anxious depression with severe insomnia (H1-mediated sedation at 7.5-15 mg), cachexia or weight loss (appetite stimulation), geriatric anxiety-depression, and SSRI augmentation for treatment resistance. Its dual mechanism — alpha-2 autoreceptor blockade increasing noradrenaline and serotonin release, plus postsynaptic 5-HT2A/2C/3 antagonism directing serotonin to the anxiolytic 5-HT1A receptor — bypasses reuptake inhibition entirely. The dose-sedation paradox (7.5-15 mg heavily sedating; 30-45 mg less sedating due to noradrenergic offset) requires careful dose selection. Open-label GAD data show 79.5% response rate, but double-blind trials have not robustly replicated this. No sexual dysfunction is a genuine advantage over SSRIs. Combination with SSRIs/SNRIs ('California rocket fuel') is pharmacologically rational but requires monitoring for additive sedation.

Question 4

Can I combine mirtazapine with an SSRI for treatment-resistant anxiety?

Accepted Answer

Mirtazapine is not first-line for uncomplicated GAD, but is strategically valuable in specific contexts: anxious depression with severe insomnia (H1-mediated sedation at 7.5-15 mg), cachexia or weight loss (appetite stimulation), geriatric anxiety-depression, and SSRI augmentation for treatment resistance. Its dual mechanism — alpha-2 autoreceptor blockade increasing noradrenaline and serotonin release, plus postsynaptic 5-HT2A/2C/3 antagonism directing serotonin to the anxiolytic 5-HT1A receptor — bypasses reuptake inhibition entirely. The dose-sedation paradox (7.5-15 mg heavily sedating; 30-45 mg less sedating due to noradrenergic offset) requires careful dose selection. Open-label GAD data show 79.5% response rate, but double-blind trials have not robustly replicated this. No sexual dysfunction is a genuine advantage over SSRIs. Combination with SSRIs/SNRIs ('California rocket fuel') is pharmacologically rational but requires monitoring for additive sedation.

PsychHQ

Mirtazapine for Anxious Patients: When It Beats SSRIs and How Its Dose-Sedation Paradox Works